Last reviewed · How we verify
Agitation associated with Bipolar Mania
Approved treatments
- Abilify · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Zyprexa · Eli Lilly
- Abilify · Generic (originally Otsuka/BMS)
Third-generation antipsychotic that acts as a partial agonist at D2 and 5-HT1A receptors, stabilizing dopamine activity rather than simply blocking it. - Zyprexa · Washington University School of Medicine
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Agitation associated with Bipolar Mania patent landscape — cliff calendar, originator estates, attackable patents
- Agitation associated with Bipolar Mania treatment landscape brief
- Agitation associated with Bipolar Mania treatment updates RSS
Frequently asked questions about Agitation associated with Bipolar Mania
What drugs treat Agitation associated with Bipolar Mania?
Tracked treatments include Abilify, Zyprexa.
What is the treatment for Agitation associated with Bipolar Mania?
Standard treatment for Agitation associated with Bipolar Mania includes Abilify, Zyprexa. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Agitation associated with Bipolar Mania patent cliff · Agitation associated with Bipolar Mania CI report
- Treatment: Abilify · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Treatment: Zyprexa · Eli Lilly
- Treatment: Abilify · Generic (originally Otsuka/BMS)
- Treatment: Zyprexa · Washington University School of Medicine
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing